Many patients taking proteasome inhibitors for multiple myeloma are concerned about drug resistance. Myeloma can change its genetic properties, rendering even the most up-to-date drugs ineffective. How might we counteract the instability in myeloma cells? In this video, Dr. Paul Richardson, a principal investigator in the Phase III PANORAMA-1 trial, gives an update on histone deacetylase – or HDAC – therapy from the 2014 annual meeting of the American Society of Clinical Oncology (ASCO).

Editor’s Note: During ASCO 2014, it was revealed that the manufacturer of panobinostat, Novartis Pharmaceuticals, had filed an application for FDA approval in March 2014. It subsequently was granted priority review by the U.S. regulatory agency.

Read the transcript |

Dr. Richardson is the Clinical Director of the Jerome Lipper Center for Multiple Myeloma at the Dana-Farber Cancer Institute.

View more programs featuring Dr. Richardson |

Get email alerts |

Subscribe on YouTube |
Like on Facebook |
Follow on Twitter |
Like on Google Plus |

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…